No abstract

LA and LV global longitudinal strain is significantly decreased in patients with DM1, which may be an early marker of subclinical dysfunction in these patients.

Background and Aims There is little information on the incremental prognostic importance of frailty beyond conventional prognostic variables in heart failure (HF) populations from different country income levels. Methods A total of 3429 adults with HF (age 61 ± 14 years, 33% women) from 27 high-, middle- and low-income countries were prospectively studied. Baseline frailty was evaluated by the Fried index, incorporating handgrip strength, gait speed, physical activity, unintended weight loss, and self-reported exhaustion. Mean left ventricular ejection fraction was 39 ± 14% and 26% had New York Heart Association Class III/IV symptoms. Participants were followed for a median (25th to 75th percentile) of 3.1 (2.0–4.3) years. Cox proportional hazard models for death and HF hospitalization adjusted for country income level; age; sex; education; HF aetiology; left ventricular ejection fraction; diabetes; tobacco and alcohol use; New York Heart Association functional class; HF medication use; blood pressure; and haemoglobin, sodium, and creatinine concentrations were performed. The incremental discriminatory value of frailty over and above the MAGGIC risk score was evaluated by the area under the receiver-operating characteristic curve. Results At baseline, 18% of participants were robust, 61% pre-frail, and 21% frail. During follow-up, 565 (16%) participants died and 471 (14%) were hospitalized for HF. Respective adjusted hazard ratios (95% confidence interval) for death among the pre-frail and frail were 1.59 (1.12–2.26) and 2.92 (1.99–4.27). Respective adjusted hazard ratios (95% confidence interval) for HF hospitalization were 1.32 (0.93–1.87) and 1.97 (1.33–2.91). Findings were consistent among different country income levels and by most subgroups. Adding frailty to the MAGGIC risk score improved the discrimination of future death and HF hospitalization. Conclusions Frailty confers substantial incremental prognostic information to prognostic variables for predicting death and HF hospitalization. The relationship between frailty and these outcomes is consistent across countries at all income levels.

Resumo Algumas infecções virais sistêmicas podem estar relacionadas ao desenvolvimento de complicações vasculares, como trombose venosa profunda e linfedema de membros inferiores e superiores. Essa relação já está bem estabelecida em pacientes portadores do vírus da imunodeficiência humana (HIV), hepatite C ou influenza. Recentemente introduzido no continente americano (2013), o vírus chicungunha, um arbovírus transmitido pelo mosquito do gênero Aedes e agente etiológico da febre chicungunha (FC), ainda não tem essa relação bem sedimentada. Porém, o surto de FC, ocorrido entre 2015 e 2016, fez com que fossem descritos na literatura médica os primeiros casos de complicações vasculares agudas e crônicas secundárias à infecção por essa arbovirose. Neste relato de caso, descrevemos uma paciente que desenvolveu linfedema de membros superiores e inferiores após quadro de FC.

IntroductionPerforator veins (PVs) play an important role in the development of chronic venous insufficiency and ulceration. Procedures to eliminate incompetence and reflux in PV may include open surgery, subfascial endoscopic surgery, intravenous ablation techniques and sclerotherapy. With the aim of filling the evidence gap, this is a protocol for a systematic review that will assess the effects of any form of intervention for the treatment of pathologic PVs of the lower limbs in patients with chronic venous disease.Methods and analysisSystematic searches will be carried out in MEDLINE, EMBASE, Cochrane CENTRAL, IBECS and LILACS databases at a minimum without date or language restrictions for relevant randomised controlled trials (RCTs) and quasi-RCTs (trials in which the method of allocation is not truly random). In addition, a search will also be carried out in the WHO International Clinical Trials Registry Platform, in the clinical trial registries of ClinicalTrials.gov and in the grey literature source OpenGrey.eu. The RCT and quasi-RCT comparison techniques isolated or in combination for treating PVs will be considered. Three review authors will independently perform data extraction and quality assessments of data from included studies, and any disagreements will be resolved by discussion. The primary outcomes will be wound healing and pain. Secondary outcomes will include oedema, adverse events, recurrence or recanalisation, quality of life and economic aspects. The Cochrane handbook will be used for guidance. If the results are not appropriate for a meta-analysis in RevManV.5 software (eg, if the data have considerable heterogeneity and are drawn from different comparisons), a descriptive analysis will be performed.Ethics and disseminationEthics committee approval is not necessary. We intend to update the public registry used in this review, report any important protocol amendments and publish the results in a widely accessible journal.PROSPERO registration numberCRD42018092974

No abstract

No abstract

Funding Acknowledgements Type of funding sources: None. Background Cancer survivors are challenging patients, as they often present increased cardiovascular (CV) risk. In this background, cardio-oncology rehabilitation frameworks for specific cancer patients have been proposed. However, optimal program designs, as well as their overall safety and efficacy in different subsets of patients, are not fully ascertained. Purpose To assess the impact of a cardio-oncology rehabilitation based framework for cancer patients at increased CV risk, compared to a community-based exercise training (CBET), on cardiorespiratory fitness (CRF) and cardiovascular risk factor (CVRF) control. Methods The CORE study was a single-center, prospective, randomized controlled trial enrolling adult cancer survivors exposed to cardiotoxic cancer treatment (anthracycline, radiotherapy on thoracic wall, anti-human epidermal growth factor receptor-type 2 drugs) and/or with previous CV disease. Participants were randomized to an 8-week center-based CR program (CBCR) or CBET, twice a week. Primary endpoint was CRF (assessed by the VO2peak, derived from a symptom-limited cardiopulmonary exercise test, performed on a treadmill); secondary endpoints were physical activity [International Physical Activity Questionnaire (IPAQ)], psychosocial parameters [Hospital Anxiety and Depression Scale (HADS)], blood pressure, body composition, lipid profile and health literacy [Newest Vital Sign (NVS) questionnaire]. Results 80 patients were included (mean age 54.5±14,12, 61 women; 66% breast cancer, 27.5% lymphoma); 75 patients completed the intervention (CBCR N= 38; CBET N=37). There was a significant improvement in the CBCR compared to the CBET group in VO2peak (∆ +2.1±2.8 vs +0.8±2.5 mL.kg-1.min-1, p=0.033) and in the following outcomes: resting systolic blood pressure (p<0.0001); body mass index (p<0.0001), lean and fat body mass (p<0.0001), waist circumference (p<0.0001); total cholesterol (p =0.001), triglycerides (p =0.008) and LDL cholesterol (p =0.003); HADS Anxiety score (p =0.003) and Depression score (p =0.009), weekly physical activity levels (p<0.0001) and health literacy scores (p<0.0001). No major CV events were reported. Conclusion The CORE trial demonstrates superior results of a CBCR regarding CRF and CVRF control. Given the higher cardiovascular risk in several groups of cancer patients, our data provides novel insights into optimized preventive strategies in this complex patient population.